Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
50 participants
INTERVENTIONAL
2016-11-30
2018-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Lymphedema is an abnormal amount of fluid that causes swelling, usually in the arms or legs. The most common presentation of lymphedema is in the upper extremities due to breast cancer treatment (Maclellean RA et al). As such, standards of care for management of lymphedema are primarily derived from the cancer research literature and involve the extremities (Moffatt CJ. 2003 QJM). The current gold standard treatment for patients with extremity lymphedema is complete decongestive therapy (CDT) (Zuther 2013). CDT is a multimodal therapy consisting of four components: manual lymph drainage, compression wrapping, exercise, and skin care (Zuther 2013).These same therapeutic techniques of CDT have been employed at Our Lady of the Lake Regional Medical Center (OLOLRMC) and adapted to treat patients with facial trauma with anecdotally good results primarily related to cosmesis. To the best of our knowledge, no clinical studies examining the effect of lymphedema treatment in the management of blunt facial trauma currently exist.. Beyond the consideration of cosmesis, we also seek to determine if this intervention improves clinical outcomes such as time to swallowing and reduced time utilizing mechanical ventilation. This study will prospectively evaluate the use of complete decongestive therapy to test the hypothesis that this intervention results in improved clinical outcomes in patients with blunt facial trauma.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Specific Aims Specific Aim I: To determine whether complete decongestive therapy can significantly reduce facial lymphedema as measured by a previously established facial composite scoring protocol.
Specific Aim II: To determine whether complete decongestive therapy can improve clinical outcomes for patients with facial trauma Study Objective and Endpoints Study Objective The primary objective of this study is to determine the effect(s), if any, of complete decongestive therapy in the management of facial trauma.
Primary Endpoint The primary endpoint will be the composite facial score measured on the day of discharge from the Trauma Neuro Critical Care (TNCC) intensive care unit (ICU) at OLOLRMC. This measurement is based on the Head \& Neck Lymphedema (HNL) program at MD Anderson Cancer Center (MDACC) whose standard evaluation protocol includes specific point-to-point measurements of the face (Smith \& Lewin 2010; Smith and Lewin 2014). A series of key facial measurements are totaled to provide a "composite facial score". Based on the clinical experience at MDACC with more than 150 patients, their HNL program has developed criteria to define clinically detectable improvements in external HNL. Those criteria are a drop in lymphedema stage or a minimum threshold of 2% reduction in the composite measurement equating to at least a 2-cm change in absolute values (Smith \& Lewin 2014).
Secondary endpoints
Because the facial and neck composite scores only provide evaluation of the extent of edema, we also seek to assess patient outcomes with regards to the following:
1. Stage of lymphedema as defined by the MDACC HNL edema rating scale
2. Number of mechanical ventilation days
3. Narcotic pain medicine utilization
4. Steroid utilization
5. Pain scale scores as determined by the Visual Analog Scale or the adult non-verbal pain score
6. Time to swallowing
7. ICU length of stay (ICULOS)
8. Hospital length of stay (LOS)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control Group
The control group will receive standard speech therapy treatments but not lymphedema treatment and will serve as the baseline for comparison for assessment of the effects of CDT.
No interventions assigned to this group
Active Treatment Group
The active treatment group will receive standard speech therapy treatments in addition to complete decongestive therapy from a certified Speech Language Pathologist (CCC-SLP) trained in CDT.
Complete Decongestive Therapy (CDT)
CDT is a multimodal therapy consisting of four components: manual lymph drainage, compression wrapping, exercise, and skin care
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Complete Decongestive Therapy (CDT)
CDT is a multimodal therapy consisting of four components: manual lymph drainage, compression wrapping, exercise, and skin care
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presence of facial trauma as determined by X-ray or computed tomography (CT)
* Presence of face/neck lymphedema characterized as at least Stage 1 on the MD Anderson Cancer Center's Head and Neck Lymphedema (HNL) rating scale
Exclusion Criteria
* Presence of injury to the carotid artery or jugular veins
* Presence of upper quadrant deep vein thrombosis
* Presence of known infection
* Unwilling or unable to consent (or unable to find an appropriate surrogate)
* Pregnant
* Expected death within 24 hours of enrollment, or desire by patient of family to pursue palliative rather than aggressive, supportive care
* Inability to speak English such that assessment of primary endpoints would not be feasible
* Prisoners
* Patients previously enrolled in another clinical trial
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Our Lady of the Lake Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Danielle Tatum
Academic Research Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Danielle Tatum, PhD
Role: STUDY_DIRECTOR
OUR LADY OF THE LAKE RMC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Our Lady of the Lake Regional Medical Center
Baton Rouge, Louisiana, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Danielle Tatum, Ph.D.
Role: primary
Hollis O'Neal, MD, MSc
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Glynn SM, Asarnow JR, Asarnow R, Shetty V, Elliot-Brown K, Black E, Belin TR. The development of acute post-traumatic stress disorder after orofacial injury: a prospective study in a large urban hospital. J Oral Maxillofac Surg. 2003 Jul;61(7):785-92. doi: 10.1016/s0278-2391(03)00239-8.
Rankin M, Borah GL. Perceived functional impact of abnormal facial appearance. Plast Reconstr Surg. 2003 Jun;111(7):2140-6; discussion 2147-8. doi: 10.1097/01.PRS.0000060105.63335.0C.
Maclellan RA, Couto RA, Sullivan JE, Grant FD, Slavin SA, Greene AK. Management of Primary and Secondary Lymphedema: Analysis of 225 Referrals to a Center. Ann Plast Surg. 2015 Aug;75(2):197-200. doi: 10.1097/SAP.0000000000000022.
Glynn SM, Shetty V, Elliot-Brown K, Leathers R, Belin TR, Wang J. Chronic posttraumatic stress disorder after facial injury: a 1-year prospective cohort study. J Trauma. 2007 Feb;62(2):410-8; discussion 418. doi: 10.1097/01.ta.0000231556.05899.b0.
Moffatt CJ, Franks PJ, Doherty DC, Williams AF, Badger C, Jeffs E, Bosanquet N, Mortimer PS. Lymphoedema: an underestimated health problem. QJM. 2003 Oct;96(10):731-8. doi: 10.1093/qjmed/hcg126.
Cohen MD. Complete decongestive physical therapy in a patient with secondary lymphedema due to orthopedic trauma and surgery of the lower extremity. Phys Ther. 2011 Nov;91(11):1618-26. doi: 10.2522/ptj.20100101. Epub 2011 Aug 25.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
9521
Identifier Type: -
Identifier Source: org_study_id